Bone Marrow Transplantation Articles & Analysis
12 news found
At the same time, HLA plays a vital role in organ and bone marrow transplantation and is also associated with serious adverse reactions to different medications. Therefore, HLA typing is essential to the research of immune-related diseases, the screening of vaccine and drug target populations, the study of ethnic evolution, tissue, organ ...
Three patients have at least 12 months of follow-up, and all remain in morphological complete remission (CR); two patients have remained progression-free for more than two years (26.5 months and 24.2 months) and a third for more than one year (12.5 months) post-transplant at the time of abstract submission. Immune system reconstitution through the first 100 days post-treatment ...
The USA boasts better cancer survival rates than most other developed countries. This was made possible due to a number of factors. In America, much attention is paid to medical equipment. Local oncology centers are equipped with the latest technology, actively use innovative technologies and new medicines. In addition, oncology in the United States involves extensive screening and more ...
While early transplant can help patients, they inevitably develop motor disease. FBX-101, a systemic AAV therapy administered after hematopoietic stem cell transplantation, was well tolerated in the first patient and the initial clinical data support normal brain development during this period of rapid myelination, and normal gross motor function,” stated ...
At one year, the overall survival without allogeneic hematopoietic stem cell transplantation across the cohort is 100% based on the Kaplan-Meier estimate. ...
(Nasdaq: MCRB), a leading microbiome therapeutics company, will present preclinical findings tomorrow at the European Bone Marrow Transplantation (EBMT) Annual Meeting that suggest SER-155 works by targeting the host immune response, potentially allowing patients undergoing hematopoietic stem cell transplantation (HSCT) to avoid ...
Multi-virus prevention has the potential to transform the management of transplant patients, who currently have limited to no approved treatment options for these infections that threaten patient survival. ...
ByKalaris
Beveridge was previously Chief Medical Officer, McKesson Specialty Health |The US Oncology Network, Executive Vice President/Medical Director and Chairman, Public Policy and Bone Marrow Transplantation, at US Oncology, and Chief Medical Officer at Humana, Inc. He also served as Co-Director of Bone Marrow ...
The first patient was treated with the investigational CardiAMP autologous cell therapy at the University of Wisconsin in Madison, by Interventional Cardiologist and Associate Professor of Medicine Amish Raval, M.D., supported by Peiman Hematti, M.D., Bone Marrow Transplantation Hematologist and Professor of Medicine. ...
“With medical partners that provide bone-marrow transplants and other major treatments, we serve many children with compromised immune systems. ...
Right now, the only effective long-term treatment for sickle cell disease is a bone marrow transplant, but that requires a patient to have a matched donor – something that is hard to find. ...
The group most at risk are people who have undergone organ (bone marrow) transplants and cancer treatment. In this group, infection with A. fumigatus is often lethal, with mortality rates of 60-90% and occurs in 25 % of haematology patients. ...